Health Care Equipment and Supplies Equities Scrutiny -- Accuray, Globus Medical, ResMed, St. Jude Medical, and Antares Pharma

LONDON, August 18, 2014 /PRNewswire/ --

On Friday, Aug 15, 2014, the NASDAQ Composite ended at 4,464.93, up 0.27%, the Dow Jones Industrial Average finished the session at 16,662.91, down 0.30% and the S&P 500 closed at 1,955.06, down 0.01%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.11% higher at 716.21, and the index has advanced 0.78% in the previous one month. Investor-Edge has initiated coverage on the following equities: Accuray Inc. (NASDAQ: ARAY), Globus Medical Inc. (NYSE: GMED), ResMed Inc. (NYSE: RMD), St Jude Medical Inc. (NYSE: STJ), and Antares Pharma Inc. (NASDAQ: ATRS). Free research on these five companies can be accessed at:  

http://investor-edge.com/register

Accuray Inc.'s stock advanced 0.90% on Friday, ending the session at $7.81. A total of 0.56 million shares were traded, below its three months average volume of 0.65 million shares. The stock moved between $7.74 and $7.97 during the session. Shares in Accuray Inc. have gained 4.97% in the previous three trading sessions, while the shares have lost 3.58% in the last one month and 10.23% from the beginning of 2014. The stock is trading below its 50-day and 200-day moving averages. The stock's 50-day moving average of $8.51 is below its 200-day moving average of $8.68. Moreover, Accuray Inc.'s stock has a Relative Strength Index (RSI) of 42.94. Sign up and read the free notes on ARAY at:

http://www.Investor-Edge.com/ARAY-18Aug2014

On Friday, shares in Globus Medical Inc. recorded a trading volume of 0.91 million shares, above its three months average volume of 0.62 million shares. The stock finished the day at $18.43, which was 1.55% lower its previous day's closing of $18.72, and registered an intraday range of $18.25 and $18.97. Shares in Globus Medical Inc. have fallen by 0.54% in the previous three trading sessions and 18.31% in the last one month. Additionally, the company's shares have lost 8.67% on YTD basis. Shares in Globus Medical Inc. are trading below their 50-day and 200-day moving averages of $22.66 and $22.57, respectively. Furthermore, the stock traded at a PE ratio of 20.52 and has an RSI of 28.45. The complimentary notes on GMED can be downloaded as in PDF format at:

http://www.Investor-Edge.com/GMED-18Aug2014

ResMed Inc.'s stock edged 0.27% lower on Friday, closing the day at $51.40. The stock recorded a trading volume of 0.52 million shares, which was below its three months average volume of 0.82 million shares. The stock oscillated between $51.04 and $51.97 during the session. The stock traded at a PE ratio of 21.15. Shares in ResMed Inc. have gained 0.49% in the previous three trading sessions and 5.65% in the last one month. Moreover, the company's shares have advanced 9.18% since the start of this year. ResMed Inc.'s shares are trading above their 50-day and 200-day moving averages of $50.86 and $48.07, respectively. Additionally, ResMed Inc.'s stock has an RSI of 56.99. Register for free on Investor-Edge and access the latest research on RMD at:

http://www.Investor-Edge.com/RMD-18Aug2014

Shares in St Jude Medical Inc. fluctuated between $62.61 and $63.95 before ending Friday's session 0.80% lower at $63.24. The stock reported a trading volume of 1.21 million shares, which was below its three months average volume of 1.59 million shares. St Jude Medical Inc.'s stock has advanced 0.06% in the previous three trading sessions and 2.08% on YTD basis, although, the stock has declined 5.30% in the last one month. Shares in St Jude Medical Inc. are trading below their 50-day and 200-day moving averages of $67.10 and $63.95, respectively. Further, the company's shares traded at a PE ratio of 16.66 and have an RSI of 33.46. The complete research on STJ is available for free at:

http://www.Investor-Edge.com/STJ-18Aug2014

On Friday, shares in Antares Pharma Inc. fell by 1.38%, closing the session at $2.14. A total of 1.17 million shares were traded, which was below its three months average volume of 1.30 million shares. The stock moved between $2.12 and $2.20 during the session. Antares Pharma Inc.'s stock has gained 9.18% in the previous three trading sessions, while the stock has declined 2.28% over the last one month and 52.14% from the beginning of 2014. The shares are trading below its 50-day and 200-day moving averages of $2.50 and $3.52, respectively. Furthermore, Antares Pharma Inc.'s stock has an RSI of 46.81. Free in depth research on ATRS is available at:

http://www.Investor-Edge.com/ATRS-18Aug2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED